Skip to main content

Currently Skimming:

Appendix B: Workshop Agendas and Questions to Panelists
Pages 181-192

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 181...
... Marilyn Albert, Johns Hopkins University School of Medicine, Division of Cognitive Neuroscience David Matchar, Duke University Medical School, Center for Clinical Health Policy Research 181
From page 182...
... Barry Berger, Exact Sciences Corporation Margaret Piper, Blue Cross and Blue Shield Association Technology Evaluation Center Richard Goldberg, University of North Carolina, Chapel Hill Atiqur Rahman, Food and Drug Administration, Center for Drug Evaluation and Research Question & Answer/Open Discussion 3:00 Break 3:15 Panel 4 -- Experts React. Moderator: Hal Sox, Vice Chair, IOM Committee Daniel Cain, Cain Brothers Peter Juhn, Health Policy and Evidence, Johnson & Johnson Cindy Mulrow, University of Texas and the American College of Physicians David Ransohoff, University of North Carolina Chapel Hill, School of Medicine Earl Steinberg, Resolution Health
From page 183...
... Panel 2 -- Lucentis/Avastin • Was the substantial uptake in Avastin use for wet AMD justifiable given the lack of evidence and the needs of the patient population? • How do evidence reviewers and payers address the relative effectiveness of Lucentis and Avastin given the limited data?
From page 184...
... AGENDA -- WORKSHOP 2 Institute of Medicine Committee on Reviewing Evidence to Identify Highly Effective Clinical Services January 25, 2007 National Academy of Sciences Building 2101 Constitution Avenue, NW, Lecture Room, Washington, DC 8:30 Welcome and introductory remarks -- Barbara McNeil, Chair, Institute of Medicine Committee 8:35 Panel 1 -- Using Systematic Reviews to Develop Clinical Recommendations. Moderator: Richard Marshall Carolyn Clancy, Agency for Healthcare Research and Quality Mary Barton, U.S.
From page 185...
... Moderator: Dana Goldman Richard Justman, UnitedHealthcare Kay Dickersin, Cochrane USA Jean Slutsky, AHRQ Effective Health Care Program Naomi Aronson, BCBSA Technology Evaluation Center Question & Answer/Open Discussion 12:30 Lunch 1:00 Panel 4 -- Stakeholders Forum. Moderator: Robert Galvin Kathy Buto, Johnson & Johnson Art Small, Genentech Vivian Coates, ECRI Jim Weinstein, Dartmouth-Hitchcock Medical Center Question & Answer/Open Discussion
From page 186...
... Consumers Union's Best Buy Drugs Program relies on evidence-based analyses of the safety and effectiveness of prescription drugs to help consumers choose the drug best suited to their medical needs. The American Heart Association (in collaboration with the American College of Cardiology)
From page 187...
... JCAHO's ORYX initiative incorporates outcome performance measurement into the accreditation process for health care organizations. The AMA-convened Physician Consortium for Performance Improvement® (Consortium)
From page 188...
... ? Institute of Medicine Workshop Reviewing Evidence to Identify Highly Effective Clinical Services January 25, 2007 Panel 3 -- Approaches to Priority Setting: Identifying Topics and Selection Moderator: Dana Goldman Panelists: Richard Justman (UnitedHealthcare)
From page 189...
... AHRQ's Effective Health Care Program is the leading federal agency charged with systematically reviewing and synthesizing evidence on clinical effectiveness. BCBSA TEC, an AHRQ-designated Evidence-based Practice Center, is a highly respected source of evidence-based assessments of the clinical effectiveness of medical procedures, devices, and drugs.
From page 190...
... 3. Several groups and individuals -- perhaps most recently Gail Wilensky in a Health Affairs piece -- have proposed the establishment of a sizable entity to effect a quantum leap in the national capacity to assess the comparative effectiveness of health care services.
From page 191...
... The U.S. Preventive Services Task Force evaluates evidence and develops recommendations for clinical preventive services. How would your organization respond to the formation of a similar task force that provided the same function for clinical interventions, e.g., diagnostic testing, treatment, etc?


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.